Slate Run Pharmaceuticals
Slate Run Pharmaceuticals lists 8 drug products in the FDA National Drug Code directory.
Products
| NDC | Product | Strength | Type |
|---|---|---|---|
| 70436-232 | Amiodarone Hydrochloride Injection, Solution | Amiodarone Hydrochloride 50 mg/mL | Rx |
| 70436-151 | Arformoterol Tartrate Inhalation Solution | Arformoterol Tartrate 15 ug/2mL | Rx |
| 70436-019 | Azithromycin Injection, Powder, Lyophilized, For Solution | Azithromycin Dihydrate 500 mg/5mL | Rx |
| 70436-203 | Dobutamine Injection | Dobutamine Hydrochloride 250 mg/20mL | Rx |
| 70436-227 | Fluconazole Powder, For Suspension | Fluconazole 40 mg/mL | Rx |
| 70436-209 | Levoleucovorin Calcium Injection, Solution | Levoleucovorin Calcium 10 mg/mL | Rx |
| 70436-210 | Levoleucovorin Calcium Injection, Solution | Levoleucovorin Calcium 10 mg/mL | Rx |
| 70436-029 | Voriconazole Injection, Powder, Lyophilized, For Solution | Voriconazole 200 mg/1 | Rx |
Recalls by Slate Run Pharmaceuticals
- D-0343-2026 Mar 4, 2026 · Class III
Labeling: Not Elsewhere Classified. The carton for Eptifibatide Injection 75 mg/100 mL states 75 mg/100 mL vial for weight-adjusted bolus dosing. The approved statement is 75 mg/100 mL vial for… - D-0279-2025 Mar 26, 2025 · Class II
CGMP deviations: The presence of nitrosamine impurity above the acceptable daily intake limits. - D-0278-2025 Mar 26, 2025 · Class II
CGMP deviations: The presence of nitrosamine impurity above the acceptable daily intake limits.